Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02151539 · ClinicalTrials.gov registry record
Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)
A clinical trial, sponsored by Vanderbilt-Ingram Cancer Center.
- Terminated
- Registry status
- 19
- Enrollment target
NCT02151539: Clinical Trial study, sponsored by Vanderbilt-Ingram Cancer Center.
NCT02151539 is a clinical trial that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 19 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02151539 was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.
- TERMINATED
- Registry status
- 19 participants
- Enrollment target
Study Summary
This research trial studies medical chart review in determining outcomes of second-line therapy in patients with acute graft-versus-host disease previously treated with extracorporeal photopheresis or other systemic therapies. Gathering information about second-line therapy in patients with acute graft-versus-host disease may help doctors learn more about the disease and find better treatment.
Primary Outcome
Rates of 6 m FFTF will be estimated by subtracting rates of total failures from 100%.
Interventions
- OTHER medical chart review
- OTHER quality-of-life assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-08-29 |
| Est. Completion | 2018-10-11 |
Why NCT02151539 stopped before completion
NCT02151539 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 19 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which medical chart review is the first listed.
NCT02151539 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02151539 about?
NCT02151539 is a clinical study titled "Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)". This research trial studies medical chart review in determining outcomes of second-line therapy in patients with acute graft-versus-host disease previously treated with extracorporeal photopheresis or other systemic therapies. Gathering information about second-line therapy in patients with acute gr...
What is the current status of trial NCT02151539?
This trial is currently terminated. The enrollment target is 19 participants. The study started on 2014-08-29. Estimated completion is 2018-10-11.
What interventions are being tested in trial NCT02151539?
The interventions under investigation include: medical chart review (OTHER), quality-of-life assessment (OTHER).
Who is sponsoring clinical trial NCT02151539?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03207464 · 19 participants · Phase 1
Molecular Imaging of NET Using [C-11]MRB-PET in MS
- NCT04318717 · 19 participants · Phase 2
Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma
- NCT05103904 · 19 participants · Phase 2
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
- NCT05607407 · 19 participants · Phase 2
Methimazole in Patients With Progressive Glioblastoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI